ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$0.39 USD
-0.03 (-7.21%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.37 -0.02 (-4.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRPH 0.39 -0.03(-7.21%)
Will PRPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRPH
Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
PRPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) Q2 Earnings and Revenues Surpass Estimates
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
Other News for PRPH
Is PRPH preparing to trend lower? 200 Day Moving Average Resistance shows up after sinking 1.07%
Is PRPH heading for a slide? Fell Below 200 Day Moving Average shows up after declining 2.79%
ProPhase Labs Partners with ThinkEquity for $6M Placement
200 Day Moving Average Support appears for PRPH after 1.02% move
200 Day Moving Average Support appears for PRPH after 0.83% move